Cumulative Index 1991

Volume 17

February AIDS AND RHEUMATIC DISEASE, pages 1–195
May NUTRITION AND RHEUMATIC DISEASES, pages 197–456
August IMAGING OF RHEUMATIC DISEASES, pages 457–823
November Pediatric Rheumatology, pages 825–1038

Note: Page numbers of issues and articles are in boldface type

Abscess, magnetic resonance imaging of, epidural, 775, 778, 784, 787 in foot, 531

paraspinal, 784, 787, 790

muscle (pyomyositis), in HIV infection, 152–153

Acetaminophen, in juvenile rheumatoid arthritis, 992

Achilles tendon, magnetic resonance imaging of, 633-634

Acquired immunodeficiency syndrome. See also Human immunodeficiency virus infection.

manifestations of, in immunosuppressive therapy, 39

prognosis vs. HLA-B35 in, 110

Reiter's syndrome in, 33-34 subacute oligoarthritis in, 49

symptom expression in, mechanism of, 158

Activities of daily living, therapy for, 1012 Acute-phase reactants, dietary fish oil effects on, 239

fasting effects on, 354

Acyclovir, in HIV infection, 144

Adaptive equipment, for activities of daily living, 1012

Adjuvant arthritis, food allergy in, 251–257
AIDS. See Acquired immunodeficiency
syndrome; Human immunodeficiency

virus infection.
"AIDS foot," in spondyloarthropathy, with
HIV infection, 46

AIDS-related complex, arthritis in, 33

Alfalfa seeds/sprouts, in SLE pathogenesis, 324–330

Allergic granulomatosis, HIV infection with, 133

Allergy, food, 243-249

antigen absorption in, 292-294

arthritis in, animal model for, 251-257 classification of, 244

definition of, 274

diagnosis of, 244-245, 344-346

false, definition of, 274 fasting and, 366–367

in inflammatory arthritis, 264-266 in juvenile rheumatoid arthritis, 406

in palindromic rheumatism, 264 in rheumatoid arthritis, 264–266

in SLE, 264

in vasculitis, 266

management of, 247-248 mechanisms of, 243-244

milk. See under Milk.

pathogenesis of, 243–244 pseudo. See *Pseudo-food allergy*. screening tests for, 245–247

verification testing in, 247 Alpha linolenic acid, metabolism of, 237,

Ambulation, physical therapy for, in pediatric disease, 1006, 1012–1013

American College of Rheumatology, position statement on diet and arthritis, 443–444 Amino acids, deficiencies of, autoimmune

disease and, 224-225

Amino acids (Continued)

distribution of, in fasting, 352-353

in SLE pathogenesis, 323-332 Amyloids, dietary fish oil effects on, 239

Anaphylaxis, 244

Anemia, autoimmune hemolytic, alfalfa seeds and, 325, 327, 329

in HIV infection, 164

in juvenile rheumatoid arthritis, 404-405 in SLE, 923-924

Aneurysms, coronary artery, in Kawasaki disease, 910-912

Angiitis, lymphocytic, HIV infection with, 136

of central nervous system, HIV infection with, 138-140

Angiocentric immunoproliferative lesions, HIV infection with, 135–138, 142

Animal models, for HIV infection, 5–23, 36– 37

Ankle. See also Foot.

computed tomography of, 552-553

juvenile rheumatoid arthritis of, physical therapy for, 1007–1008

Ankylosing spondylitis, absence of, in HIV infection, 47 imaging of, 813–816

vs. Reiter's syndrome, 61

Anorexia, in juvenile rheumatoid arthritis, 404

Anti-CD4 antibodies, in juvenile rheumatoid arthritis, 903

Anti-CD5 antibodies, in juvenile rheumatoid arthritis, 903

Anti-DNA antibodies, in glomerulonephritis, 215, 219

Anti-erythrocyte antibodies, in HIV infection, 164

Antibodies. See also Immunoglobulin(s). anti-idiotypic, in IgA deficiency, 298–299 formation of, dietary omega–3 fatty acids effects on, 219–220

in HIV infection, autoimmunity and, 162-169

to bacterial antigens, gastrointestinal, 310 to food antigens, in IgA deficiency, 298– 299

in infants, 290-292

Anticardiolipin antibodies, in HIV infection, 50, 166-167

Anticollagen antibodies, in HIV infection, 167

Antidepressants, tricyclic, in juvenile rheumatoid arthritis, 992

Antigens, bacterial, arthritis and, 309-321 IgA and, 309-310

in inflammatory bowel disease, 312-313

in intestinal bypass syndrome, 313-314, 366 in pseudomembranous colitis, 315-316

in Whipple's disease, 314 pathogenetic principles in, 316 postdysenteric reactive, 311–312 spondyloarthropathies, 315

therapeutic considerations in, 316 vs. food antigens, 310

deposition of, in arthritis, 861

endogenous, mast cells response to, 338 food. See Food antigens.

Antimalarial drugs, in juvenile rheumatoid arthritis, 874, 878–879, 897 Antineutrophil cytoplasmic antibodies, in

HIV infection, 165
Antinuclear antibodies, in dermatomyositis,

932-933 in HIV infection, 163

in SLE, kidney dysfunction risk and, 923

Arachidonic acid, chemical structure of, 213 metabolism of, 373-378

autoimmune disease and, 227 omega-3 fatty acids and, 378-385 plant seed oils and, 416

synthesis of, 227 in fasting, 357

Arthralgia, in HIV infection, 83

Arthritis. See also specific type.

adjuvant, food allergy in, 251-257 collagen-induced, fish oil diet effects on,

dry, 528

experimental, fish oil fatty acids and, 235-242

food and, 259-272, 314-315 gastrointestinal tract and, 263-264

historical perspective on, 259–262 gastrointestinal tract antigens and, 309–

gastrointestinal tract antigens and, 309–321 in caprine arthritis-encephalitis virus in-

n caprine arthritis-encephalitis virus infection, 11–12 pathogenesis of, 15–19, 36–37

in eosinophilia-myalgia syndrome, L-tryptophan-induced, 430

in HIV infection. See under Human immunodeficiency virus infection.

in inflammatory bowel disease, 312–313 in intestinal bypass syndrome, 313–314, 366

in pseudomembranous colitis, 315–316 in Whipple's disease, 314 inflammatory. See also Rheumatoid ar-

thritis.
of elbow, magnetic resonance imaging
of, 711

mast cells in, 333-342

parasitic, 315 postdysenteric reactive, 311-312

rheumatoid. See Rheumatoid arthritis. septic. See Septic arthritis.

tuberculous, arthrography of, 523-524,

unproved remedies for, 197-202, 273-285, 346-347, 406-407

Arthrography, aspiration with, 506, 508 in rheumatic disease, 505-542

cysts, 534, 537-538

iliopsoas bursa distension, 533-534 indications for, 531-538

mechanically unstable, 532-533 monoarticular abnormalities, 516-530 pigmented villonodular synovitis, 516,

rheumatoid arthritis, 531

septic arthritis, 505-515

subacromial-subdeltoid bursa distension, 534, 537

synovial chondromatosis, 523

tuberculous arthritis, 523-524, 528 with soft-tissue mass, 533-534, 537-538

of knee, 531

of naviculolunate dissociation, 532

of popliteal cyst, 803 of rotator cuff, 533, 795-796

of shoulder, 795-796

of wrist, 531 in instability, 532-533

vs. magnetic resonance imaging, 617-618

Arthropathy, hemophilic, magnetic

resonance imaging of, 662-663 Arthroplasty, in juvenile rheumatoid arthritis, 971-983

indications for, 973-974 of hip, 973-980

of knee, 973-974, 980-982

preoperative planning in, 971-972 resection, 979-980 revisional, 978

Ascorbic acid (vitamin C), deficiency of, autoimmune disease and, 228 immune responses to, 206-207 in rheumatoid arthritis, 266

Aspiration, of joint, arthrography in, 506,

Aspirin, in Kawasaki disease, 912-914 Atlantoaxial joint disorders, in rheumatoid

arthritis, 757-760 precautions in, 1003

Auranofin, in juvenile rheumatoid arthritis,

Aurothioglucose, in juvenile rheumatoid arthritis, 875

Aurothiomalate, in juvenile rheumatoid arthritis, 875

Autoantibodies, induction of, in HIV infection, 157-176

Autoimmune disease. See also specific

nutritional modulation of, 223-234 amino acids, 224-225

calories, 225-226

lipids, 226-228. See also Fatty acids. minerals, 229-231. See also specific mineral.

omega-3 fatty acids in, 213-222 protein, 224-225

vitamins, 228-229

Autoimmune hemolytic anemia, alfalfa seeds and, 325, 327, 329

Autoimmunity, in juvenile rheumatoid arthritis, 844

Autologous mixed lymphocyte reaction, in juvenile rheumatoid arthritis, 845

Avascular necrosis, of bone, in HIV infection, 49-50

of foot, magnetic resonance imaging of,

of hip (femoral head), computed tomography of, 549 imaging algorithm for, 799-802

magnetic resonance imaging of, 671-

of knee, magnetic resonance imaging of,

of wrist, magnetic resonance imaging of,

Azathioprine, in arthritis, with HIV infection, 39

in dermatomyositis, 939

in juvenile rheumatoid arthritis, 897, 903

AZT (azidothymidine). See Zidovudine. Azulfidine, in arthritis, with HIV infection,

B lymphocytes, in HIV infection, 158-162 in juvenile rheumatoid arthritis, 846-847 Bacteria, antigens to, arthritis and, 309-321 in gastrointestinal tract, dietary therapy effects on, 281-282 fasting effects on, 368 immune response to, arthritis in, 309-

Bacteriophage OX 174, in juvenile rheumatoid arthritis, 845

Baker's cyst. See Popliteal cyst.

Bankart fractures, magnetic resonance imaging of, 701

Behavioral management, of pain, in juvenile rheumatoid arthritis, 992-993 in reflex sympathetic dystrophy, 994-

Biceps tendon, ultrasonography of, 496 Biopsy, of salivary glands, in Sjögren's syndrome, 101

Biotin deficiency, immune responses to, 206 Bipolar hemiarthroplasty, in juvenile rheumatoid arthritis, 978-979

Bluhm scoring method, for rheumatoid arthritis, 466

Body composition, in juvenile rheumatoid arthritis, 408

Body outline, in Pediatric Pain Questionnaire, 990

Bone, avascular necrosis of, in HIV infection, 49-50

infection of. See Osteomyelitis. of knee, magnetic resonance imaging of, 647, 650-651

ultrasonography of, 487 Bone grafting, in facial scleroderma

reconstruction, 962–963

Bone marrow transplantation, food antigen absorption in, 301–303

Borage seed oil, antiinflammatory effects of, 416, 418

Botanical lipids, as immune response modulators, 415–425

Bradykinin, in pain mechanism, 992 Breathing exercises, in pain management, 993

Bursitis, in HIV infection, 83, 150-151

CAEV (caprine arthritis-encephalitis virus) infection, HIV infection and, 5–23, 36– 37

Calcinosis, in dermatomyositis, 935-936, 939-940

Caloric restriction. See also Fasting, in autoimmune disease, 225–226 in rheumatoid arthritis, 358

Campylobacter infection, in reactive arthritis, 312-313

Campylobacter jejuni infection, in arthritis, 33

Canavanine, immunomodulatory role of, 330–331

in SLE pathogenesis, 325-330

Candidiasis, gastrointestinal, dietary therapy effects on, 282

in arthritis pathogenesis, 33

Caprine arthritis-encephalitis virus infection, HIV infection and, 5-23, 36-37

Cardiovascular effects, of Kawasaki disease, 910–912

of L-tryptophan-induced eosinophiliamyalgia syndrome, 430

Carotenoid deficiency, immune responses to, 204–206

Carpal tunnel syndrome, magnetic resonance imaging of, 722, 727 Cartilage, ultrasonography of, 487

Casting, in juvenile rheumatoid arthritis, 1004–1008

CD4+ cells, in arthritis, 37-38

in diffuse infiltrative lymphocytosis, 106–108

in HIV infection, 69, 158–159, 161, 165 CD8+ cells, in arthritis, 37–38

in diffuse infiltrative lymphocytosis syndrome, 102, 105–108

in HIV infection, 69

in Reiter's syndrome, with HIV infection, 53–54

CD29+ cells, in diffuse infiltrative lymphocytosis, 107-108

CD45R+ cells, in diffuse infiltrative lymphocytosis, 107

Celiac disease, arthritis in, 315 fasting and, 367–368 pathogenesis of, 280

Cell-mediated allergic reaction, 244

Cellular immunity, in juvenile rheumatoid arthritis, 845–847 Cellulitis, magnetic resonance imaging of, in

foot, 631 with osteomyelitis, imaging of, 567

Central nervous system, primary angiitis of, HIV infection with, 138–140

Cervical spine, degenerative disorders of, 741–755

anatomic considerations in, 741–743 apophyseal joint involvement in, 747 clinical aspects of, 745, 747 computed tomography of, 749–750 diarthroidal joint involvement in, 744– 745

discovertebral joint involvement in, 743-744

entheses, 745

facet syndrome, 747

intervertebral disk involvement in, 743–745, 747

ligamentous ossification, 747 magnetic resonance imaging of, 750– 753

osteophytes in, 747 pathophysiology of, 743-745

radiculopathy in, 747 radiography of, 749

spinal canal stenosis, 747

juvenile rheumatoid arthritis of, physical therapy for, 1002-1003

rheumatoid arthritis of, 757–772 atlantoaxial subluxation in, 757–760 computed tomography of, 763–765 magnetic resonance imaging of, 765–

769 management of, 769 myelography of, 764–765 myelopathy in, 767–769

odontoid erosions in, 762–763 pannus in, 763, 769

pathophysiology of, 757-763 progression of, 763 radiography of, 763 subaxial subluxation in, 760, 762 Chlamydia infection, in arthritis

pathogenesis, 33, 65

Chlorambucil, in juvenile rheumatoid arthritis, 902–903 in vasculitis, 144

Chloroquine, in juvenile rheumatoid arthritis, 878-879, 893

Chondromalacia patellae, computed tomography of, 552

Chondromatosis, synovial, arthrography of, 523

Churg-Strauss syndrome, HIV infection with, 133

Clostridium difficile infection, arthritis in, 861

Clostridium infection, gastrointestinal, arthritis with, 315–317, 366 dietary therapy effects on, 282

Coat protein (gp120), in interleukin expression, 9–10

Cobblestoned synovium, 519

Codeine, in juvenile rheumatoid arthritis, 992

Coeliac disease. See Celiac disease.

Colchicine, in calcinosis, 939 Cold, in physical therapy, 1010

Colitis, arthritis with, pseudomembranous, 315–316

ulcerative, 312–313 Collagen, autoantibodies against, in HIV

infection, 167 Collagen-induced arthritis, fish oil diet effects on, 215

Collateral ligament injuries, magnetic resonance imaging of, 645, 647

Common variable immunodeficiency, food antigen handling in, 299–301

Compartment syndrome, of foot, magnetic resonance imaging of, 631

Complement levels, fasting effects on, 354 Computed tomography, in ankylosing spondylitis, 814

in arthritis, 505-542

of ankle, 552–553 of cervical spine, 763–765

of foot, 553-554 of hip, 549, 551

of knee, 551-552

of sacroiliac joints, 548-549 of shoulder, 547-548

of sternoclavicular joint, 544–545, 547 vs. plain radiography, 543–544

in avascular necrosis, of hip, 800 in degenerative disorders, of spine, 749-

of sacroiliac joints, 548-549, 810 vs. magnetic resonance imaging, 617 Concavalin A, in juvenile rheumatoid arthritis, 845

Conditioning exercises, in juvenile rheumatoid arthritis, 1008-1009

Congenital immunodeficiency, food antigen absorption in, 294-301

Connective tissue diseases. See also specific disease.

HIV infection with, in Zimbabwe, 89-97

Contractures, in juvenile rheumatoid arthritis, hip, 1005–1006 knee, 1007

Copper, deficiency of, immune responses to, 210

Copper bracelets, in arthritis, 266

Coronary artery aneurysms, in Kawasaki disease, 910-912

Corticosteroids, in arthritis, with HIV infection, 54, 85

in dermatomyositis, 938-939

in diffuse infiltrative lymphocytosis, 111–112

in juvenile rheumatoid arthritis, nutritional effects of, 405

in Kawasaki disease, 913

in psoriasis, with HIV infection, 66

in psoriatic arthritis, with HIV infection, 68

in Reiter's syndrome, with HIV infection, 68 in L-tryptophan-induced eosinophilia-

myalgia syndrome, 433 Coxsackievirus, in dermatomyositis etiology,

Coxsackievirus, in dermatomyositis etiology, 932 Cranial neuropathy, in diffuse infiltrative

lymphocytosis, 105 Crohn's disease, arthritis with, 312–313

Cruciate ligament injuries, of knee, magnetic resonance imaging of, 645

Cryoglobulinemia, HIV infection with, 186– 187

Cryptococcus neoformans infection, in septic arthritis, 151

Cunninghamella bertholletiae infection, in septic arthritis, 152

Cyclooxygenase pathway, in fatty acid metabolism, 373–376, 380

Cyclophosphamide, in dermatomyositis, 939 in juvenile rheumatoid arthritis, 897, 903 in SLE, 924–927

Cyclosporine, in arthritis, with HIV infection, 55-56

in dermatomyositis, 938

in juvenile rheumatoid arthritis, 885–886, 903

in psoriasis, 71-72 in SLE, 927

Cyst(s), Baker's. See Popliteal cyst. ganglion. See Ganglion cyst. of knee. See also Popliteal cyst. Cyst(s) (Continued) magnetic resonance imaging of, 652,

popliteal. See *Popliteal cyst*. ultrasonography of, 487–488

Cytokines, in juvenile rheumatoid arthritis, 847-851

in Kawasaki disease, 910

in synovial fluid, in retrovirus infection, 18–19

interactions with eicosanoids, 235-236 Cytotoxic drugs, in dermatomyositis, 938-

in juvenile rheumatoid arthritis, 893

Dactylitis, in spoodyloarthropathy, with HIV infection, 46

Deep vein thrombosis, in rheumatoid arthritis, 805-808

Deflazacort, in dermatomyositis, 939 Dental malocelusion, in facial scleroderma, 963–966

in juvenile rheumatoid arthritis, 943–953 DeQuervain's synovitis, magnetic resonance

imaging of, 738
Dermatomyositis, HIV infection with, 31
clinical features of, 120–122
pathogenesis of, 125–127
treatment of, 123–125

juvenile, 931–942 clinical aspects of, 933–934 diagnosis of, 934–935 etiology of, 932–933 incidence of, 931–932 management of, 938–940 physical therapy for, 1013 prognosis for, 935–938 relapse in, 936–937

Diabetes mellitus, foot disorders in, magnetic resonance imaging of, 620,

osteomyelitis with, imaging of, 574–575 Diarrhea, reactive arthritis after, 311–312 Diary, of food/symptoms, in food allergy diagnosis, 245

2',3'-Dideoxyinosine, in HIV infection, with systemic lupus erythematosus, 180

Diet. See also Food.

diagnostic, elimination-challenge, 245, 344–346 in SLE pathogenesis, 323–324

therapeutic, fasting in. See Fasting. in arthritis, 273–285

challenge studies in, 279 elimination of symptom-causing foods in, 275–276

literature review on, 276-280 problems with, 276

reasons for improvement with, 280-283

types of, 274

in juvenile rheumatoid arthritis, 410-411

in rheumatoid arthritis, 391-402 omega-3 fatty acids in. See Fatty acids, omega-3.

plant seed oils in, 415-425

Diffuse infiltrative lymphocytosis, HIV infection with, 99-115, 137-138, 168 clinical features of, 102-106 immunogenetics of, 109-110 in pediatric patients, 106 lymphocyte subpopulations in, 106-108 management of, 110-112 serology of, 108-109 vs. Sjögren's syndrome, 99-102

Dihomogamma linolenic acid, antiinflammatory effects of, 416, 418– 422

as prostaglandin precursor, 237 Dipyridamole, in Kawasaki disease, 913 Discoid meniscus, magnetic resonance

imaging of, 644-645 Discovertebral osteochondrosis, 744

Docosahexaenoic acid, as dietary supplement, in rheumatoid arthritis, 392–398

macrophage activity and, 236 metabolism of, 373–376 omega-3 fatty acids and, 378–385

Docosahexaenoic acid esters, immune response and, 216 Dong diet, in rheumatoid arthritis, 277

Double-blinded oral provocation test, in food allergy, 344–345

Drugs. See also specific drug and disease. in juvenile rheumatoid arthritis, 871–889 combinations of, 880–884, 902–903 disease course and, 872–873 efficacy of, 897–898 experimental, 884–886 for pain management, 991–992 new approaches to, 901–904 nutritional effects of, 405 slow-acting, 873–880 toxicity of, 874–875. See also specific

drug. vs. unproved remedies, 197–202 Dysentery, reactive arthritis after, 311–312

ECHO virus, in dermatomyositis etiology, 932

Eicosanoids, interactions with cytokines, 235-236

Eicosapentaenoic acid, as dietary supplement, in rheumatoid arthritis, 392-398

autoimmune disease and, 228 cellular activity of, 236–237 chemical structure of, 213 macrophage activity and, 236–237 metabolism of, 373–378

omega-3 fatty acids and, 378-385 synthesis of, in fasting, 357

precursors in, 237
Eicosapentaenoic acid esters, immune response and, 216

Eicosatetraenoic acid derivatives, 378. See also Leukotrienes.

Elbow, juvenile rheumatoid arthritis of, physical therapy for, 1003–1004 magnetic resonance imaging of 705–721

magnetic resonance imaging of, **705–720** anatomic considerations in, **705–707** in effusions, **709–710** in inflammation, **711** in neoplasms, **711**, **713**, **719** in trauma, **710–711**

in trauma, 710–711 techniques for, 707–709 Electrical stimulation, in physical therapy,

in reflex sympathetic dystrophy pain, 994 Elimination-challenge test, in food allergy

diagnosis, 245 Emotional factors, in pseudo-food allergy, 346–348

Endurance exercises, in juvenile rheumatoid

arthritis, 1008-1009 Enterotoxins, in arthritis, 861-862

Enthesopathy, in psoriatic arthritis, with HIV infection, 66

in Reiter's syndrome, 28 in spondyloarthropathy, with HIV infection, 46–48

eno gene, in retroviruses, 5–7 Eosinophilia-myalgia syndrome, Ltryptophan-induced, 427–441 clinical manifestations of, 428–432 etiology of, 434–435 laboratory features of, 432–433 pathogenesis of, 435–437

pathology of, 428–431 prognosis for, 434 treatment of, 433–434

Eosinophilic vasculitis, in HIV infection, 140 Epidural abscess, magnetic resonance imaging in, 775, 778, 784, 787

Epstein-Barr virus infection, rheumatoid arthritis and, 864–866

Sjögren's syndrome and, 102 Erythema elevatum diutinum, in HIV infection, 140

Erythema infectiosum, arthritis in, 866 Erythema nodosum-like lesions, in HIV infection, 31 Erythrocytes, autoantibodies against, in HIV infection, 164

Etretinate, in arthritis, with HIV infection, 55

in psoriasis, with HIV infection, 67 in psoriatic arthritis, with HIV infection, 39

Evening primrose seed oil, antiinflammatory effects of, 416, 418, 421-422

Exercise, conditioning, 1008-1009 endurance, 1008-1009

in juvenile rheumatoid arthritis, 405, 1002–1009

range of motion, 1002-1008 strengthening, 1002-1008

Facial reconstruction, 943-969 in juvenile rheumatoid arthritis, 943-953 in scleroderma, 953, 956-966

Factor VIII-related antigen, in dermatomyositis, 933

Faradic electrical stimulation, in physical therapy, 1010

Fasting, 351-371

antiinflammatory effects of, 354–356, 363–365

food antigens and, 366–367 gastrointestinal effects of, 365–368 general effects of, 351–353, 364–365 immunomodulatory effects of, 354–356 in rheumatoid arthritis, 264, 277, 356– 358, 363–371

intestinal flora and, 368 intestinal permeability and, 367-368 methods for, 353-354, 364-365 weight loss in, 351-352

Fat (body), abnormalities of, in dermatomyositis, 937-938

Fat (dietary), autoimmune disease and, 226-228

Fatty acids, in plant seed oils, immune response effects of, 415-425 omega-3, 213-222

acute-phase reactants levels and, 239 amyloid levels and, 239 antibody formation and, 219–220 antiinflammatory effect of, 219–220 cellular pools of, 236–237 in autoimmune disease, 227–228 in collagen-induced arthritis, 235–239 in experimental arthritis, 235–242 in hypercalcemia reduction, 220 in immune complex modulation, 215–

216 in murine autoimmune disease, 214– 216

in plant seed oils, 415

Fatty acids (Continued)

in platelet-activating factor synthesis. 378-379

in prostaglandin inhibition, 220 in rheumatoid arthritis, 283, 373-389,

391-402 infection resistance and, 221

inflammation mediator synthesis and, 373-389

by cyclooxygenase pathway, 380 by 5-lipoxygenase pathway, 380-386 in healthy persons, 382-384 leukocyte function and, 384-385 neutrophil function and, 385-386 pathways for, 375-378

platelet activating factor, 378-379 tissue phospholipid composition and, 216-219

serum levels of, in fasting, 357

Femoral head, avascular necrosis of. See under Hip.

Fibrinopeptide A, in dermatomyositis, 933 Fibromyalgia, juvenile, pain in, 995-996 Fibrosis, in L-tryptophan-induced

eosinophilia-myalgia syndrome, 436-437

Fifth disease, arthritis in, 866 Fingers, juvenile rheumatoid arthritis of, physical therapy for, 1004-1005

Fish oils. See also Fatty acids, omega-3. types of, 391-392

Folic acid deficiency, immune responses to,

Folk (unproved) remedies, for arthritis, 197-202, 273-285, 346-347, 406-407

Folliculitis, necrotizing, in HIV infection,

Food. See also Diet: Nutrition.

arthritis and, 259-272 gastrointestinal tract and, 263-264 historical perspective on, 259-262

as unproved remedy, 197-202, 346-347, 406-407

in SLE pathogenesis, 323-332 intolerance to, candidiasis with, 282

definition of, 274 dietary therapy effects on, 280

secretory IgA in, 281 sensitivity to, 274-275

tolerance to, mechanisms for, 292

Food allergy. See under Allergy. Food antigens, 287-307

absorption of, in allergy, 292-294 in bone marrow transplantation, 301-

in common variable immunodeficiency,

in congenital immunodeficiency, 294-

in immaturity, 290-292

normal 287-289

antibodies to, 289

autologous anti-idiotypic, 298-299 in infants, 290-291

clearing of, by immunoglobulin infusion, 299-301

dietary therapy effects on, 281

exclusion from gastrointestinal tract, 287-289

fasting and, 366-367

immunologic effects of, arthritis and, 309-311, 314-316

spondyloarthropathies, 315

in allergy, 292-294

in common variable immunodeficiency,

in IgA deficiency, 295-299 in infants, 291-292

in blood, 289

oral tolerance to, in IgA deficiency, 299 in infants, 292 Foot. See also Ankle.

computed tomography of, 553-554 enthesopathy of, in spondyloarthropathy, with HIV infection, 46

juvenile rheumatoid arthritis of, physical therapy for, 1008

magnetic resonance imaging of, 617-636 in arthritis, 620, 625-626

in avascular necrosis, 632 in compartment syndrome, 631

in fractures, 632-633 in infection, 620, 631-632

in ischemia, 632

in soft-tissue pathology, 633-634 rationale for, 620

technical considerations in, 618 vs. other imaging techniques, 617-618

osteomyelitis of, imaging of, 574-575 ultrasonography of, in tendon disorders,

Foreign bodies, in magnetic resonance imaging, 603-604

in soft tissue, ultrasonography of, 502 Fractures, magnetic resonance imaging of,

elbow, 710-711 foot, 632-634

hip, 680, 682 knee, 650

shoulder, 701 osteomyelitis with, imaging of, 575-576

Freedman-Steinberg scoring method, for rheumatoid arthritis, 462

Freiberg's disease, magnetic resonance imaging of, 632

Gadolinium-enhanced (contrast) magnetic resonance imaging, of spinal infection, 785-792

advantages of, 790 disk space, 786–787 epidural abscess, 787 limitations of, 790–791 meningitis, 790 myelitis, 790 osteomyelitis, 786–787 paraspinal abscess, 787, 790 vs. normal spine appearance, 785 gag gene, in retroviruses, 5–7

Gallium-67 radiopharmaceuticals, in arthritis imaging, 586, 589 in bone disorder imaging, 560-561, 567, 570-572, 576

Games, in physical therapy, 1011–1012 Gamma globulin, intravenous. See Immunoglobulin(s), intravenous.

Gamma linolenic acid, antiinflammatory effects of, 416, 418–419, 421–422 as prostaglandin precursor, 237

Ganglion cyst, of knee, magnetic resonance imaging of, 652

of wrist, magnetic resonance imaging of, 727

ultrasonography of, 496

tarsal, magnetic resonance imaging of, 634 Gastrointestinal tract, dietary therapy effects on, 281–282

in fasting, 365–368 food antigen absorption in, in bone mar-

row transplantation, 302–303 in congenital immunodeficiency, 294, 299

in food allergy, 292 in immaturity, 290 normal, 287–289

immune response of, arthritis and, 309-321

food-induced, 314–315 inflammatory bowel disease and, 312–313

intestinal bypass syndrome and, 313– 314, 366

parasitic, 315 pathogenetic principles in, 316

postdysenteric reactive, 311–312 pseudomembranous colitis and, 315– 316

spondyloarthropathies, 315 therapeutic considerations in, 316 Whipple's disease and, 314

permeability of, 365–368 Genant scoring method, for rheumatoid arthritis, 464, 466

Gender, prostaglandin synthesis and, 238– 239

Genetic susceptibility, to juvenile rheumatoid arthritis, 825–826 Genome, of retroviruses, 5–11 Girdlestone pseudoarthrosis, in juvenile rheumatoid arthritis, 979–980 Glenohumeral joint instability, magnetic

Glenohumeral joint instability, magnetic resonance imaging of, 698-701

Glomerulonephritis, autoimmune, dietary omega-3 fatty acids and, 214-216 zinc deficiency and, 230-231

Gluten, allergy to, in rheumatoid arthritis, 278

Gluten enteropathy. See Celiac disease. Goats, caprine arthritis-encephalitis virus infection in, HIV infection and, 5–23, 36–37

Gofton-O'Brien scoring method, for rheumatoid arthritis, 462, 466 Cold salts, in arthritis, with HIV infect

Gold salts, in arthritis, with HIV infection,

in juvenile rheumatoid arthritis, 874–877, 893, 897, 902–903 in psoriatic arthritis, with HIV infection

in psoriatic arthritis, with HIV infection, 39 vs. unproved remedies, 200

Graft-versus-host disease, food antigen absorption in, 301–303

Grafting, in facial scleroderma reconstruction, 960, 962–963

Granulocyte macrophage colony stimulating factor, in juvenile rheumatoid arthritis, 850

Granulomatosis, allergic, in HIV infection, 133

lymphomatoid, HIV infection with, 135-138

Growth factors, generation of, in fasting, 353 Growth hormone, in juvenile rheumatoid arthritis, 408

Growth retardation, in juvenile rheumatoid arthritis, 407–408 Guided imagery, in pain management, 993

Hand, ultrasonography of, in tendon disorders, 496

Head, juvenile rheumatoid arthritis of, physical therapy for, 1002–1003

Heat, in physical therapy, 1009

Heat shock proteins, in rheumatoid arthritis, 863-864

Hemangioma, of elbow, magnetic resonance imaging of, 719

Hematoma, ultrasonography of, 499 Hematopoietic cells, antibodies against, in HIV infection, 164–166

Hemiarthroplasty, in juvenile rheumatoid arthritis, 978–979

Hemolytic anemia, autoimmune, alfalfa seeds and, 325, 327, 329

Hemophilia, arthropathy in, magnetic resonance imaging of, 662-663 Hemophilia (Continued)

hemosiderin deposits in, magnetic resonance imaging of, 625-626

septic arthritis in, HIV infection and, 150 Hemosiderin, magnetic resonance imaging of, in foot disorders, 625-626

Henoch-Schonlein purpura, food allergy and, 266

HIV infection with, 135

Heparin, in Kawasaki disease, 913 in mast cells, 337

Hepatitis, in arthritis etiology, 860 in dermatomyositis etiology, 932

5-HEPE (5-S-hydroxy-6-trans-8,11,14-cissynthesis of, 376, 381, 383, 385

Herpes virus infections, in arthritis pathogenesis, 33

Herpes zoster infection, central nervous system angiitis in, 140

5-HETE (5-S-hydroxy-6-trans-8,11,14-cisacid), action of, 375 metabolism of, 376 synthesis of, 376, 382–385

High endothelial venules, in lymphocyte traffic control, 310

Hill-Sachs lesions, magnetic resonance imaging of, 701

Hip, anatomy of, 669-671

arthrography of, in septic arthritis, 511, 513

in synovial chondromatosis, 523 arthroplasty of, in juvenile rheumatoid ar-

thritis, 973-980 avascular necrosis of, computed tomography of, 549

imaging algorithm for, 799-802 magnetic resonance imaging in, 671-675, 800

computed tomography of, 549, 551 juvenile rheumatoid arthritis of, arthroplasty in, 973–980

physical therapy for, 1005-1006 magnetic resonance imaging of, 669-692

anatomic considerations in, 669-671 in avascular necrosis, 671-675

in congenital dislocation, 686 in infection, 682, 684

in inflammatory arthritis, 684

in Legg-Calvé-Perthes disease, 675 in osteoarthritis, 684

in pediatric patients, 684, 686

in pigmented villonodular synovitis, 684 in rheumatoid arthritis, 684

in stress fractures, 680, 682 in transient osteoporosis (marrow

edema syndrome), 675, 677, 680 in transient synovitis, 686

Histamine, in pain mechanism, 992 release from mast cells, 334, 336 L-Histidine, in rheumatoid arthritis, 267 Histocompatibility antigens. See HLA molecules; Major histocompatibility complex molecules.

Histoplasma capsulatum infection, in septic arthritis, 151-152

HIV infection. See Acquired immunodeficiency syndrome; Human immunodeficiency virus infection.

HLA-B27, in arthritis, with HIV infection, 68-70

in Reiter's syndrome, 95 with HIV infection, 53

HLA-B35, AIDS prognosis and, 110 HLA-DR, in diffuse infiltrative

lymphocytosis, 109-110

HLA molecules, in juvenile rheumatoid arthritis, 826–833, 844 pauciarticular-onset, 833–836 polyarticular-onset, 836–838 systemic-onset, 838–839 in psoriasis/psoriatic arthritis, 61–62 with HIV infection, 68–70

in Reiter's syndrome, 61–62 5-HPEPE (5-S-hydroperoxy–6-trans– 8,11,14-cis-eicosapentaenoic acid),

synthesis of, 376, 381 5-HPETE (5-S-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid), synthesis of, 374, 376, 381

Human immunodeficiency virus, genomic structure of, 5–11 immune response to, 158

in joint tissue, 34-35 life cycle of, 6

Human immunodeficiency virus infection, AIDS symptoms expression in, 158

animal models for, 5–23 antibody response to new antigens and, 159–160

anticardiolipin antibodies in, 50, 166-167 arthralgia in, 83

arthritis with, 81–82, 861. See also specific type of arthritis. acute symmetric polyarthritis, 48–49

clinical course of, 29 clinical syndromes in, 45–50 direct role of HIV in, 52–53

epidemiology of, 50-51 histopathology of, 14-15

immunogenetics of, 51–52, 68–69, 95, 109–110

in Zimbabwe, **89–97** infection in, 32–34, 52, 62–64 nosology of, 44–45

nursing considerations in, 56-57 of undetermined type, 82-83

pathogenesis of, 51–54 peripheral, 27–29

physical therapy in, 56-57

psoriatic. See under Psoriatic arthritis.

Reiter's syndrome. See under Reiter's syndrome.

rheumatoid, 94, 183–185 septic. 149–156

spinal, 29-30, 46-47 treatment of, 54-56

autoantibody induction in, 157–176 avascular necrosis of bone in, 49–50

B cells in, 158–162 caprine retrovirus infections and, 5–23, 36–37

central nervous system angiitis with, 138-140

connective tissue diseases with, 89–97 cryoglobulinemia with, 186–187 cytokine expression in, 18

dermatomyositis in, 935

diffuse infiltrative lymphocytosis syndrome with, 99-115, 137-138, 168

enthesopathy in, 28, 46–48, 66 eosinophilic vasculitis with, 140 erythema elevatum diutinum with, 140 interferon levels in, 72

Lyme disease with, 185-186 lymphocytic angiitis with, 136

myalgia in, 83–84

necrotizing folliculitis with, 140 of synovium, 52-53

opportunistic infections in, 126-127, 141, 151-154

ovine retrovirus infections and, 5-23 painful rheumatic syndromes with, 49,

79–87. See also specific disease. pathophysiology of, 157–169 peripheral neuropathy in, 84–85 polyarteritis nodosa-like syndromes in,

132–133 polymyositis with, 117–129, 169 Reiter's syndrome with. See under *Rei*-

Reiter's syndrome with. See under Reiter's syndrome.
rheumatic syndromes with, 49, 79–87

case studies in, 177-188 risk factors for, in Zimbabwe, 94-95

seborrheic dermatitis in, 66 Sjögren's syndrome with, 168

soft-tissue rheumatism in, 83–84 spondyloarthropathy with, 43–58

systemic lupus erythematosus with, 177– 183

vasculitis with, 131–147, 169, 186–187 Human leukocyte antigens. See HLA molecules; Major histocompatibility

complex molecules. 5-S-Hydroperoxy-6-trans-8,11,14-ciseicosapentaenoic acid, synthesis of, 376,

5-S-Hydroperoxy–6-trans–8,11,14-ciseicosatetraenoic acid, synthesis of, 374, 376, 381 5-S-Hydroxy-6-trans-8,11,14-ciseicosapentaenoic acid, synthesis of, 376, 381, 383, 385

5-S-Hydroxy-6-trans-8,11,14-ciseicosatetraenoic acid, action of, 375 metabolism of, 376 synthesis of, 376, 382-385

Hydroxychloroquine, in dermatomyositis, 939

in juvenile rheumatoid arthritis, 874, 878-879, 902-903

Hypercalcemia, dietary omega-3 fatty acids effects on, 220

Hyperglobulinemia, in HIV infection, 158 Hypersensitivity, to food. See Allergy, food. Hypersensitivity vasculitis, HIV infection with, 134–135

Hypertension, pulmonary, in SLE, 923-924

Ice packs, in physical therapy, 1010 Ig. See Immunoglobulin(s).

Iliopsoas bursa, distended, arthrography of, 533–534

533-534
Imaging, in rheumatic disease. See
Arthrography; Computed tomography;
Magnetic resonance imaging; Nuclear
medicine techniques; Radiography;
Ultrasonography; specific disease and

Immune complexes, allergic reactions to,

clearance of, immunoglobulin infusion in, 299–301

in HIV infection, 163-164 in IgA deficiency, 297-298

in infants on cows' milk diet, 291–292

in intestinal bypass syndrome, 313–314 in rheumatoid arthritis, 859–860

omega-3 fatty acids effects on, 215-216 Immune response, carotenoid deficiency

and, 204-206 in food allergy, 244, 292-294

in Kawasaki disease, 909-910 iron deficiency and, 208-209

juvenile rheumatoid arthritis and, 843– 857

cellular, 845-847

clinical aspects of, 843-844 cytokines in, 847-851

etiology and, 844 modulators of, canavanine as, 330-331

fasting and, 354-356 plant seed oils and, 415-425

nutrient deficiencies and, 203-212, 223-234

of gastrointestinal tract, 309–311 protein energy malnutrition and, 203–204 protein restriction and, 224–225 Immune response (Continued)

to food antigens, in allergy, 292-294 in common variable immunodeficiency,

in IgA deficiency, 295-299 in infants, 291-292 normal, 288-289

vitamin deficiencies and, 204-208 zinc deficiency and, 209-210

Immunodeficiency See also Acquired immunodeficiency syndrome; Human immunodeficiency virus infection. congenital. food antigen handling in. 294-

301 in animal viral disease, 11-12, 17-18

Immunogenetics, of arthritis, with HIV infection, 51–52

of diffuse infiltrative lymphocytosis, 109– 110

of juvenile rheumatoid arthritis, 825-842 of psoriasis/psoriatic arthritis, with HIV infection, 68-69

of Reiter's syndrome, with HIV infection, 95

Immunoglobulin(s). See also Antibodies. excess production of, in juvenile rheumatoid arthritis, 846–847

fasting effects on, 354

in synovial fluid, in retrovirus infection, 15–16

in vasculitis, with HIV infection, 144 intravenous, in dermatomyositis, 939 in immune complex clearance, 299–301 in juvenile rheumatoid arthritis, 886 in Kawasaki disease, 911, 913–915 in SLE, 927

Immunoglobulin A, deficiency of, food antigen absorption in, 295–299

deposition of, in Henoch-Schoenlein purpura, 135

gastrointestinal antigens and, 309-310 Immunoglobulin E, in dermatomyositis, 935

in food allergy, 246, 292-293 in HIV infection, 159

in mast cell activity, 333-342

in rheumatoid arthritis, dietary therapy and, 277

Immunoglobulin G, in HIV infection, 158 Immunosuppressive therapy, in arthritis, with HIV infection, 39

in diffuse infiltrative lymphocytosis, with HIV infection, 111

in juvenile rheumatoid arthritis, 880–886 Implants, metal, in magnetic resonance imaging, 603–604

Indium—111 radiopharmaceuticals, bone disorder imaging, 561, 567, 570–572, 576

in arthritis imaging, 586, 589 Indomethacin, in calcinosis, 939 in psoriatic arthritis, with HIV infection, 68

in Reiter's syndrome, with HIV infection, 68

Infants, food antigens in, 290-292

Infection, bone. See Osteomyelitis. foot, magnetic resonance imaging of, 620, 631–632

hip, magnetic resonance imaging of, 682, 684

in disease pathogenesis/etiology, arthritis, 32–34, 52, 62–64

dermatomyositis, 932

Kawasaki disease, 909 rheumatoid arthritis, 859-870

reumatolu artirus, 599–510 epidemiologic aspects of, 862 Epstein-Barr virus, 864–866 inflammation pathways in, 859–862 mycobacterial, 862–864 parvovirus, 866–867

in psoriasis, 71

joint. See Septic arthritis.

opportunistic, in HIV infection, 126-127, 141, 151-154

spine. See under Spine.

susceptibility to, dietary omega-3 fatty acids effects on, 221

Inflammation, fish oil diet effects on, 214-216

mediators of, dietary omega-3 acids and. See under Fatty acids, omega-3. plant seed oils and, 415-425

synovial, mast cells in, 333–342 Inflammatory bowel disease, arthritis with, 312–313

Influenza, in dermatomyositis etiology, 932 Interferons, in arthritis, with HIV infection, 55

in Kawasaki disease, 910 in psoriasis, 71-72

Interleukin(s), expression of, coat protein in, 9–10

in juvenile rheumatoid arthritis, 903

in Kawasaki disease, 910 in mast cell activity, 334

in mast cell activity, 334 interactions with eicosanoids, 235–236

synthesis of, dietary fish oil effects on, 394, 396–398

Interleukin 1, in juvenile rheumatoid arthritis, 848-849

Interleukin-1-like molecule, in psoriasis, 71 Interleukin 2, in juvenile rheumatoid arthritis, 850

Interleukin 6, in juvenile rheumatoid arthritis, 850-851

Interstitial pneumonitis, in diffuse infiltrative lymphocytosis, 104–105 in pediatric patients, 106 management of, 111 Intervertebral disks, degeneration of, 743-745

herniation of, 747

infection of, magnetic resonance imaging in. 786-787

osteolysis of, imaging of, 813-815 Intestinal bypass syndrome, arthritis with,

313-314, 366 Intolerance, to food. See Food, intolerance

Intradermal provocation test, in food allergy

diagnosis, 246-247 Iodine, autoimmune disease and, 231

Iodine-131 radiopharmaceuticals, in arthritis imaging, 585-586

Iron deficiency, immune response to, 208-

Ischemia, of foot, magnetic resonance imaging of, 632

Jejunoileal bypass surgery, in arthritis etiology, 860

Joint(s), infection of. See Septic arthritis. prosthesis for. See also Arthroplasty. radionuclide evaluation of, 576-578 replacement of. See Arthroplasty.

JRA. See Juvenile rheumatoid arthritis. Juvenile fibromyalgia, pain in, 995-996 Iuvenile rheumatoid arthritis, arthroplasty

in. 971-983

hip, 973-980 indications for, 973-974

knee, 973-974, 980-982

preoperative planning in, 971-972 resection, 979-980

revisional, 978

autoimmunity in, 844

facial reconstruction in, 943-953 HLA molecules and, 831-833

pauciarticular-onset, 833-836

polyarticular-onset, 836-838 immune response in, 843-857

cellular, 845-847 clinical aspects of, 843-844

cytokines in, 847-851

etiology and, 844

immunogenetics of, 825-842

evidence for genetic susceptibility, 825-896

molecular basis of, 826-833 pauciarticular-onset, 833-836

polyarticular-onset, rheumatoid factornegative, 837-838

rheumatoid factor-positive, 836-837 systemic-onset, 838-839

medical treatment of, 871-889 combinations in, 880-884, 902-903 disease course and, 872-873

efficacy of, 897-898

experimental, 884-886

new approaches to, 901-904

nomenclature in, 871-872 slow-acting, 873-880

toxicity in, 874-875. See also specific drug.

mortality from, 898-899

natural history of, 872-873

nutritional aspects of, 403-413

assessment of, 409-410

dietary interventions in, 410-411

growth retardation, 407-408 protein-energy malnutrition, 408-409 risk factors in, 404-407

pain in. 985-993

assessment of, 986-987

behavioral management of, 992-993 pharmacologic management of, 991-992

questionnaire for, 988-991

pathogenesis of, 843-857

cellular immune function in, 845-847 clinical aspects of, 843-844

cytokines in, 847-851

etiology and, 844

pauciarticular-onset, immunogenetics of, 833-836

outcome of, 896

physical therapy for. See Physical therapy, in pediatric disease.

polyarticular-onset, immunogenetics of, rheumatoid factor-negative, 837-

rheumatoid factor-positive, 836-837 outcome of, 896

systemic-onset, immunogenetics of, 838-839

outcome of, 896

treatment of, arthroplasty in, 971-983

medical, 871-889

new approaches to, 901-904

outcome of, 891-905

current data on, 899-901

functional, 892-894

mortality from, 898-899

radiographic assessment of, 894-897

paradigm influence on, 897-898

physical therapy in, 1001-1014

Kaposi's sarcoma, psoriasis and, 72 viral gene role in, 8-10, 19

Kawasaki disease, 907-919 cardiovascular complications of, 910-912

clinical features of, 907 epidemiology of, 907-910

prognosis for, 910-912

treatment of, 912-915

Kaye scoring method, for rheumatoid arthritis, 464-466, 468

Keinbock's disease, magnetic resonance imaging of, 727

Kellgren scoring method, for rheumatoid arthritis, 460

Keratoconjunctivitis sicca, in diffuse infiltrative lymphocytosis syndrome, 103

in Sjögren's syndrome, 99, 101 Keratoderma blennorrhagica, in psoriatic

arthritis, 30

in Reiter's syndrome, 61

Ketanserin, in reflex sympathetic dystrophy pain, 994

Kidney dysfunction, in diffuse infiltrative lymphocytosis, 111 in SLE, risks of, 923–924

Klebsiella infection, gastrointestinal, dietary therapy effects on, 281-282

Knee, arthrography of, 531

in pigmented villonodular synovitis, 516, 519

in synovial chondromatosis, 523 arthroplasty of, in juvenile rheumatoid arthritis, 973–974, 980–982

computed tomography of, 551-552 cysts of. See also Popliteal cyst.

magnetic resonance imaging of, 652, 655

juvenile rheumatoid arthritis of, physical therapy for, 1006-1007

magnetic resonance imaging of, 637-668 collateral ligaments, 645, 647 cruciate ligaments, 645

discoid meniscus, 644-645

in avascular necrosis, 651 in bony abnormalities, 647, 650-651

in cysts, 652, 655

in fractures, 650 in hemophilic arthropathy, 662–663 in osteochondritis dissecans, 650–651

in osteonecrosis, 651

in pigmented villonodular synovitis, 655–659

in rheumatoid arthritis, 659, 662

in septic arthritis, 663 menisci, 637, 641, 643-645

ultrasonography of, in cystic disorders, 502

Kohler's disease, magnetic resonance imaging of, 632

Kynurenine substances, in L-tryptophaninduced eosinophilia-myalgia syndrome, 434–435

Lacrimal glands, destruction of, in Sjögren's syndrome, 99 Lactovegetarian diet, in rheumatoid arthritis, 276

Langerhans' cells, epidermal, in psoriasis, 70-71

Larsen scoring method, for rheumatoid arthritis, 461-462, 466

Leg length discrepancy, in juvenile rheumatoid arthritis, 1006

Legg-Calvé-Perthes disease, magnetic resonance imaging of, 675

Lentivirus infections. See also Human immunodeficiency virus infection. caprine arthritis-encephalitis virus in, 5-

23 Visna-Maede virus in, 5-23

Leukocytes, function of, dietary omega-3 fatty acids and, 384-385

Leukocytoclastic vasculitis, HIV infection with, 134-135

Leukocytosis, in juvenile rheumatoid arthritis, 409

Leukotrienes, metabolism of, dietary fish oil effects on, 396-398

synthesis of, 373, 375, 416 omega-3 fatty acids and, 236-237, 380-386

pathways for, 375-378

LFA-1, in diffuse infiltrative lymphocytosis, 107-108

Linoleic acid, arachidonic acid synthesis from, 237, 415-416

Lipids. See Fat; Fatty acids.

Lipodystrophy, in dermatomyositis, 937-938

Lipoma, of wrist, magnetic resonance imaging of, 727

Lipopolysaccharides, in arthritis etiology, 861 5-Lipoxygenase pathway, in fatty acid

metabolism, 373-378, 380-386 Liver dysfunction, in diffuse infiltrative

lymphocytosis, 105 Luschka, joints of, osteoarthritis of, 744 Lyme disease, arthritis in, 861

HIV infection with, 185–186Lymphadenopathy, in common variable immunodeficiency, 299

in diffuse infiltrative lymphocytosis, 105 Lymphocytes. See also CD4 + cells; CD8 +

cells.
antibodies against, in HIV infection, 165–

166 circulation of, high endothelial venules and, 310

function of, dihomogamma linolenic acid effects on, 420–421

in animal retrovirus infection, 16–17

in dermatomyositis, 933

in HIV infection, 158-162 in juvenile rheumatoid arthritis, 845-847 activated T cells in, 846

B-cell overactivity in, 846-847 subpopulations, 845-846 in rheumatoid arthritis, 863-864 in scleroderma, 958

Lymphocytic angiitis, HIV infection with,

Lymphocytosis, diffuse infiltrative, HIV infection with, 99-115, 137-138, 168 Lymphoma, angiocentric, HIV infection

with, 136

Lymphomatoid granulomatosis, HIV infection with, 135-138

M-cells, in gastrointestinal absorption, 365 Macrophages, in inflammatory response, dietary fish oils and, 235-239

retrovirus infection of, 13-14

Magnesium deficiency, immune responses to. 210

Magnetic resonance imaging, claustrophobia in, 599

coil selection for, 607-608

foreign body behavior in, 603-604 in juvenile rheumatoid arthritis, for synovitis assessment, 895

metal implant interference in, 600-605 of ankle. 617-636

of cervical spine, in degenerative disorders, 750-753

in rheumatoid arthritis, 765-769

of elbow, 705-720 of foot, 617-636

of hip, 669-692, 800

of knee, 637-668

of musculoskeletal system, 599-615

of rotator cuff, 697-698, 796 of sacroiliac joints, 810

of shoulder, 693-703, 796

of spine, in infection, 773-794

of wrist, 721-739

patient selection for, 599-605 positioning for, 607-608

pulse sequences for, 608-610

sedation in, 599-600

slice selection for, 610, 613 technical considerations in, 618

Major histocompatibility complex molecules. See also HLA molecules

in diffuse infiltrative lymphocytosis, 109-

in retrovirus infection, 17-18

Malnutrition, protein-energy, immune responses to, 203-204 in juvenile rheumatoid arthritis, 408-

Malocclusion, in facial scleroderma, 963-966 in juvenile rheumatoid arthritis, 943-953

Marine lipids. See also Fattu acids, omega-

types of, 391-392

Mast cells, 333-342

biology of, 333-334 in arthritis, 335-336

degranulation of, mediation of, 337-338 mediators of, 336-338

Mechanical feeding problems, in juvenile rheumatoid arthritis, 405-406

Menhaden oil, in murine autoimmune disease, 214-216

Meningitis, in diffuse infiltrative lymphocytosis, 105

magnetic resonance imaging in, 785, 790 Menisci, of knee, magnetic resonance

imaging of, 637, 641, 643-645, 652 Metal implants, in magnetic resonance imaging, 603-604

Metatarsal heads, avascular necrosis of, magnetic resonance imaging of, 632

Methotrexate, in arthritis, with HIV infection, 39

in dermatomyositis, 939

in juvenile rheumatoid arthritis, 881-884, 902-903

in psoriasis, with HIV infection, 67 in SLE, in pediatric patients, 927

Methylprednisolone, in SLE, in pediatric patients, 927

Methylprednisone, in dermatomyositis, 938-

Milk, allergy to, arthritis induced by, 251-257, 265, 314-315, 406 mechanisms of, 293

immune response to, in IgA deficiency, 294-298

in infants, 291-292 Milk proteins, absorption of, in infants, 290-

accumulation of, in hypogammaglobulinemia, 299

Millet seed synovium, 523

Minerals. See also specific mineral. deficiencies of, autoimmune disease and, 229-231

Mitogens, in juvenile rheumatoid arthritis, 845

Molecular mimicry, in rheumatic fever, 860 in rheumatoid arthritis, 865-866

Morphea, facial manifestations of, 953, 956-957, 959

MRI. See Magnetic resonance imaging. Mucormycosis, in septic arthritis, 152

Muscle(s), abscess of (pyomyositis), in HIV infection, 152-153

atrophy of, in spondyloarthropathy, with HIV infection, 48

inflammation of. See Polymyositis. ultrasonography of, 499

Muscle(s) (Continued)

weakness of, in dermatomyositis, 933-934 Muscular dystrophy, in dermatomyositis,

936-937

Myalgia, in HIV infection, 83-84 in Reiter's syndrome, 29

Mycobacterial infection, rheumatoid arthritis in, 862-864

Mycobacterium avium complex infection, in septic arthritis, 152

Myelitis, magnetic resonance imaging in, 784, 790

Myelography, of cervical spine rheumatoid arthritis, 764-765

Myelopathy, in cervical spine rheumatoid arthritis, 767-769

Myopathy. See also specific disease, e.g., Polymyositis. with HIV infection, 152–153

Myositis, ultrasonography of, 499

Nails, dystrophy of, in HIV infection, 47 in psoriasis, 60-61, 66

Navicular, avascular necrosis of, magnetic resonance imaging of, 632

Naviculolunate dissociation, arthrography of, 532

Neck joints, juvenile rheumatoid arthritis of, physical therapy for, 1002–1003
Necrosis, avascular, See Avascular necrosis.

of bone, in HIV infection, 49–50

nef gene, in retroviruses, 7–11

Neoplasms, magnetic resonance imaging of, of elbow, 711, 713, 719 of wrist, 727

Nerve block, sympathetic, in reflex sympathetic dystrophy pain, 994 Nerve stimulation, in reflex sympathetic

dystrophy pain, 994

Neuromuscular pathology, in L-tryptophaninduced eosinophilia-myalgia syndrome, 428–430

Neutrophils, autoantibodies against, in HIV infection, 165

dietary fish oil effects on, 385-386, 396 fasting effects on, 356-358

Niacin deficiency, immune responses to, 206 Nonsteroidal anti-inflammatory drugs, in

arthritis, with HIV infection, 39, 54 in juvenile rheumatoid arthritis, 902–903, 991–992

nutritional effects of, 405

intestinal permeability changes from, 367 Nörgaard view, in hand radiography, 471, 473

Nuclear medicine techniques, in ankylosing spondylitis, 814–815 in arthritis, 585–597 negative joint scan in, 590-591 osteoarthritis, 593

radiopharmaceuticals for, 585-586 sacroiliitis, 592-593, 809-810

septic, 559-583 synovitis, 586, 589-590

treatment monitoring, 595

in hip avascular necrosis, 800 in joint prosthesis evaluation, 576-578

in osteomyelitis, 559-583

Nutrition, allergic reactions in, 259–272. See also Allergy, food.

See also Allergy, food. animal model for, 251–257

American College of Rheumatology position statement on, 443-444

as unproved treatment, 197-202, 273-285, 346-347, 406-407 assessment of, in juvenile rheumatoid ar-

thritis, 409–410 deficiencies in, immune responses and,

203–212, 223–234

fasting and. See Fasting. immune responses and, 287-307

botanical lipids in, 415-425

dietary deficiencies and, 203-212, 223-234

gastrointestinal/joint interrelationships in, 309–321

hypersensitivity reactions, 243-249 mast cell activity in, 333-342

in autoimmune disease, in murine models, 223-234

omega—3 fatty acids and, 213–222 in eosinophilia-myalgia syndrome, L-tryptophan-induced, 427–441

in experimental arthritis, fish oil effects, 235–242

in juvenile rheumatoid arthritis, 403–413 in rheumatoid arthritis, 264–266, 273–285 fasting effects on, 264, 277, 356–358,

363–371 food allergy in, 251–257 juvenile, 403–413

omega-3 fatty acids and, 373-389, 391-

plant seed oils, 415-425

in systemic lupus erythematosus, 323–332 omega–3 fatty acids in. See under Fatty acids.

pseudo-food allergy in, 280, 343-349 therapeutic use of, 273-285

Obesity, fasting in, 353

Odontoid, erosions of, in cervical spine rheumatoid arthritis, 762–763

Omega-3 fatty acids. See under Fatty acids. Opportunistic infections, in HIV infection, 151-154 angioinvasive, 141 polymyositis and, 126-127

Oral gold therapy, in juvenile rheumatoid arthritis, 876–877

Orthodontic treatment, in facial scleroderma, 963-966

in juvenile rheumatoid arthritis, 943–953 Orthognathic surgery, in facial scleroderma, 965–966

Osteoarthritis, magnetic resonance imaging of, foot, 626

hip, 684

nuclear medicine techniques in, 593 of joints of Luschka, 744

Osteochondritis dissecans, magnetic resonance imaging of, elbow, 711 knee. 650-651

Osteomyelitis, in HIV infection, 152 magnetic resonance imaging in, foot, 631– 632

hip, 682, 684 spine, 786-787

nuclear medicine techniques in, 559–583 chronic, 571–573 imaging in, 567, 570–571 in adults, 566–567 in pediatric patients, 562–564, 566 radiopharmaceuticals for, 560–561 subacute, 571–573 with diabetes mellitus, 574–575 with fractures, 575–576 radiography in, 572

septic arthritis with, 506 Osteonecrosis. See Avascular necrosis. Osteophytes, of cervical spine, 747

Osteophytes, of cervical spine, 171
Osteoporosis, of hip, transient, magnetic
resonance imaging of, 675, 677, 680
Ovine retrovirus infections, HIV infection

and, 5-23

Pain. 985-1000

assessment of, in juvenile rheumatoid arthritis, 986–987

in reflex sympathetic dystrophy, 994 descriptors for, in Pediatric Pain Questionnaire, 990

in juvenile fibromyalgia, 995-996 in juvenile rheumatoid arthritis, 985-993

assessment of, 986–987 behavioral management of, 992–993 pharmacologic management of, 991–992

questionnaire for, 988–991 in reflex sympathetic dystrophy, 993–995 management of, in juvenile rheumatoid arthritis. 991–992

in reflex sympathetic dystrophy, 994-995 questionnaire for, in pediatric patients, 988–991

unproved remedies for, 200

Painful rheumatic syndromes, in HIV infection, 49, 79–87. See also specific disease.

AIDS-associated arthritis, 81-82 arthralgia, 83

characteristics of, 84-86

inflammatory arthritis of undetermined type, 82–83

peripheral neuropathy, 84 Reiter's syndrome, 79–81 soft-tissue disorders, 83–84

Palindromic rheumatism, food allergy and, 264

Pannus, in cervical spine, 763, 769 in foot, magnetic resonance imaging of, 625

Pantothenic acid deficiency, immune responses to, 206

Para-aminobenzoic acid, in scleroderma, 959 Paraffin bath, in physical therapy, 1009 Parasitic arthritis, 315

Paraspinal abscess, magnetic resonance imaging in, 784, 787, 790

Parotid gland, biopsy of, in Sjögren's syndrome, 101

enlargement of, in diffuse infiltrative lymphocytosis, 103, 106

Parvovirus, rheumatoid arthritis and, 866– 867

Patellofemoral joint, computed tomography of, 551–552 Pediatric Pain Questionnaire, 988–991

Pediatric patients, arthroplasty in, 971–983 central nervous system vasculitis in, 140 dermatomyositis in, 931–942

diffuse infiltrative lymphocytosis syndrome in, 106

facial reconstruction in, in juvenile rheumatoid arthritis, 943–953 in scleroderma, 953, 956–966

fibromyalgia in, 995–996 juvenile rheumatoid arthritis in. See Juve-

nile rheumatoid arthritis. Kawasaki disease in, 907–919

magnetic resonance imaging in, in hip disorders, 684, 686 sedation for, 599–600

pain management in, in fibromyalgia, 995–996

in juvenile rheumatoid arthritis, 985– 993

in reflex sympathetic dystrophy, 993– 995

physical therapy for, 1001–1014 reflex sympathetic dystrophy in, 993–995 scleroderma in, 953–966 systemic lupus erythematosus in, 921–930 D-Penicillamine, in juvenile rheumatoid arthritis, 874, 877–878, 893, 897 in scleroderma, 959

Pentamidine, in HIV infection, 144

Peripheral neuropathy, in diffuse infiltrative lymphocytosis, 105 in HIV infection, 84–85

in polyarteritis nodosa-like syndromes, 133

Phemister's triad, in tuberculous arthritis,

Phenylalanine deficiency, autoimmune disease and, 224

Phenylbutazone, in arthritis, with HIV infection, 54

in psoriatic arthritis, with HIV infection, 68

in Reiter's syndrome, with HIV infection, 68

Phospholipase, in omega-3 fatty acid synthesis, 373

Phospholipids, composition of, dietary omega—3 fatty acids effects on, 216–219 in omega—3 fatty acid synthesis, 373–375

Physical activity, in juvenile rheumatoid arthritis, 405

Physical therapy, in arthritis, with HIV infection, 56-57

in pediatric disease, 1001–1014 activities of daily living and, 1012 ambulation rehabilitation, 1006, 1012– 1013

1013 ankle, 1007–1008 compliance with, 1011 conditioning exercises, 1008–1009

developmental issues in, 1010-1011 elbow, 1003-1004 endurance exercises, 1008-1009

fingers, 1004-1005 foot, 1008

head and neck, 1002-1003

hip, 1005-1006 knee, 1006-1007

mobility exercises, 1012–1013

modalities for, 1009-1010 play activities in, 1011-1012

range of motion exercises, 1002–1008 reflex sympathetic dystrophy, 994–995 shoulder, 1003

strengthening exercises, 1002-1008 toes, 1008 wrist, 1004

Pigmented villonodular synovitis, arthrography of, 516, 519

magnetic resonance imaging of, hip, 684 knee, 655-659

Placebo response, in dietary therapy, 280 Plant seed oils, as immune response modulators, 415–425 Plaquenil, in arthritis, with HIV infection, 55

Plastic surgery, in facial scleroderma, 960– 966

Platelet activating factor, synthesis of, omega-3 fatty acids and, 373-375, 378-379

Play activities, in physical therapy, 1011-1012

Pneumocystis carinii, necrotizing vasculitis in, 141

Pneumonitis, interstitial, in diffuse infiltrative lymphocytosis, 104–105 in pediatric patients, 106 management of, 111

Pokeweed mitogen, in juvenile rheumatoid arthritis, 845

pol gene, in retroviruses, 5-7

Polyarteritis nodosa-like syndromes, HIV infection with, 132-133

Polyarthritis, acute symmetric, HIV infection with, 48-49

Polymyositis, HIV infection with, 117-129, 169

clinicopathological considerations in, 120–122

laboratory studies in, 119 pathogenesis of, 125–127

treatment of, 123–125 Polyunsaturated fatty acids. See also Fatty

acids, omega-3.
alpha linolenic acid, 237, 416

dihomogamma linolenic acid, 237, 416, 418-422

gamma linolenic acid, 237, 416, 418-419, 421-422

linoleic acid, 237, 415-416

Popliteal (Baker's) cyst, arthrography of, 537–538

evaluation of, 803-804

magnetic resonance imaging of, 652 pseudothrombophlebitis in, 803, 805 ultrasonography of, 502

Postdysenteric reactive arthritis, 311–312 Prealbumin level, in juvenile rheumatoid arthritis, 408–409

Precipitins, in infants, 290-291 Prednisolone, in psoriatic arthritis, with

HIV infection, 39–40
Prednisone, in arthritis, with HIV infection,

54 in dermatomyositis, 938

in myositis, with HIV infection, 123–125 Primrose seed oil, antiinflammatory effects of, 416, 418, 421–422

Proliferative responses, in juvenile rheumatoid arthritis, 845

Prostacyclin, synthesis of, 375–376 Prostaglandins, action of, 419–420 in pain mechanism, 991–992 synthesis of, 373-377

in fasting, 352

inhibition of, autoimmune disease and,

omega-3 fatty acids and, 220, 236-237, 380

plant seed oils and, 415-416, 418-420 Prosthesis, joint. See also Arthroplasty.

radionuclide evaluation of, 576–578 Protein, absorption of, in infants, 290–292 deficiency of, autoimmune disease and, 224–225

milk, 290-292, 299

Protein-energy malnutrition, immune responses to, 203-204

in juvenile rheumatoid arthritis, 408-409 Proteus infection, gastrointestinal, dietary

therapy effects on, 281–282 Pseudarthrosis, of spine, imaging of, 813– 815

Pseudo-food allergy, 343-349

diagnosis of, 344-346

in rheumatoid arthritis, 280

psychological considerations in, 346–348 Pseudomembranous colitis, arthritis in, 315–

316, 861 Pseudothrombophlebitis, in popliteal cyst, 803, 805

Psoralen, in psoriasis, with HIV infection, 66–67

in psoriatic arthritis, with HIV infection, 39

Psoriasis, definition of, 60-61

genetics of, 61-62 HIV infection with, 47, 59-77

clinical features of, 66 epidemiology of, 63-64

immunogenetics of, 52, 68–69 pathogenesis of, 69–72

treatment of, 55-56, 66-68 infection in, 62-63

pathogenesis of, 61–63

Psoriatic arthritis, definition of, 61 genetics of, 61-62

genetics of, 61–62 HIV infection with, 25–42, 59–77, 83, 93 clinical features of, 30–31, 45–48, 66

epidemiology of, 26-27, 63-66 immunogenetics of, 52, 68-69

pathogenesis of, 36-38, 69-72 pathology of, 34-36

precipitating infectious organisms in,

32-34 treatment of, 39-40, 66-68

infection in, 62-63 pathogenesis of, 61-63

vs. Reiter's syndrome, 61

Psychological factors, in pseudo-food allergy, 346–348

Pulmonary disease, in L-tryptophan-induced eosinophilia-myalgia syndrome, 430 Pulmonary hypertension, in SLE, risks of, 923-924

Pulsed ultraviolet actinotherapy (PUVA), in psoriatic arthritis, with HIV infection, 39, 66-67

Purpura, in food allergy, 266 in hypersensitivity vasculitis, with HIV infection, 134–135

PUVA therapy, in psoriasis/psoriatic arthritis, with HIV infection, 39, 66–67 Pyomyositis, in HIV infection, 152–153 Pyroxidine deficiency, immune responses to,

206

Quack (unproved) remedies, for arthritis, 197-202, 273-285, 346-347, 406-407

Radiculopathy, in cervical spine degeneration, 747

Radioallergosorbent test, in food allergy diagnosis, 246

Radiography, in ankylosing spondylitis, 814 in juvenile rheumatoid arthritis, for synovitis assessment, 894–897

in osteomyelitis, 572 in rheumatoid arthritis, for disease progression, 471-485

scoring methods and, 457-470

in septic arthritis, 506 of cervical spine, in degenerative disorders, 749

in rheumatoid arthritis, 763

of hip, in avascular necrosis, 799-800 of rotator cuff tears, 795

of sacroiliac joints, 809 of shoulder, 795

vs. computed tomography, 543-544

vs. magnetic resonance imaging, 618 Radionuclide techniques. See *Nuclear* medicine techniques.

Radiopharmaceuticals, in nuclear medicine, 560-561, 585-586

Range of motion exercises, for pediatric patients, 1002-1008

Rash, in dermatomyositis, 934 Reactive arthritis, postdysenteric, 311-312

Reconstructive surgery, in facial scleroderma, 960-966

Reflex sympathetic dystrophy, pain in, 993-

Rehabilitation. See also *Physical therapy*. in arthritis, with HIV infection, 56–57

Reiter's syndrome, bacterial antigens in, 311 genetics of, 62

HIV infection with, 25-42, 79-81 clinical features of, 27-31, 45-48, 66

toxins in, 861-862

inflammation mediator synthesis in, om-

ega-3 fatty acids in, 373-389

Reiter's syndrome (Continued) enthesopathy in, 28 epidemiology of, 26-27, 50-51, 63-66 immunogenetics of, 51-52, 68-69, 95 in Zimbabwe, 90-94 infections and, 52 nathogenesis of, 36-38, 53-54, 69-70 pathology of, 34-36 precipitating infectious organisms in, 39_34 treatment of, 39-40, 54-56, 68 incomplete, 61, 91 infection in, 62-63 vs. ankylosing spondylitis, 61 vs. psoriatic arthritis, 61 Relaxation techniques, in pain management, Resection arthroplasty, in juvenile rheumatoid arthritis, 979-980 Retinol binding protein, in juvenile rheumatoid arthritis, 408-409 Retrovirus infections. See also Human immunodeficiency virus infection. caprine, 5-23, 36-37 in arthritis, in animals, 14-19 pathogenetic mechanisms in, 15-19 ovine. 5-23 Retroviruses, cell tropism in, in animal disease, 13-14 viral gene products in, 5-11 rev gene, in retroviruses, 7-8 Rheumatic fever, molecular mimicry in, 860 Rheumatoid arthritis, arthrography of, with septic arthritis, 531 copper bracelets for, 266 deep vein thrombosis in, 805-808 dietary therapy in, 273-285 elimination of symptom-causing foods

in. 275-276

types of, 274

L-histidine in, 267

860

fasting, 356-358, 363-371

plant seed oils, 415-425 problems with, 276

fasting in, 356-358, 363-371

animal model for, 251-257

HIV infection with, 94, 183–185 infectious etiology of, 859–870 epidemiologic aspects of, 862 Epstein-Barr virus in, 864–866

immune complex deposition in, 859-

in situ antigen deposition in, 861

mycobacterial, 862-864

parvovirus in, 866-867

inflammation pathways in, 859-862 molecular mimicry in, 860

food allergy in. 264-266

literature review on, 276-280

reasons for improvement with, 280-283

by cyclooxygenase pathway, 380 by 5-lipoxygenase pathway, 380-386 pathways for, 375-378 platelet activating factor, 378-379 plant seed fatty acids and, 415-425 intestinal permeability in, 367 juvenile. See Juvenile rheumatoid arthrimagnetic resonance imaging of, 659, 662 foot, 620, 625 hip, 684 of cervical spine. See under Cervical spine omega-3 fatty acid supplementation in, 391-402 radiography in, for disease progression assessment, 471-485 clinical variables in, 476, 480 film exposure in, 474 interpretational variables in, 474 pathophysiologic variables in, 480-484 technical variables in, 471-474 views for, 471, 473 for quantitative assessment (scoring methods), 457-470 comparison of, 466-468 criteria for, 457-458 detailed, 463-466 global, 459-463 types of, 458 vitamin C in, 266 zinc supplementation in, 266-267 Rheumatoid factors, in HIV infection, 163 in juvenile rheumatoid arthritis, HLA molecules and, 836-837 Riboflavin deficiency, immune responses to, 206 RNA, of retroviruses, 5-11 Romberg's disease, facial manifestations of, 957-959, 965-966 Rotator cuff, arthrography of, 533 imaging of, 795-798 magnetic resonance imaging of, 697-698, ultrasonography of, 491, 493

Sacroiliac joints, computed tomography of, 548-549, 810 imaging of, 809-812 magnetic resonance imaging of, 810 nuclear medicine techniques for, 592-593 radiography of, 809 scintigraphy of, 809-810 septic arthritis of, aspiration of, 508 Sacroiliitis, in HIV infection, 29-30, 46-47 Salivary glands, destruction of, in diffuse infiltrative lymphocytosis, 103 in Siögren's syndrome, 99-102

Salmonella, in reactive arthritis, 311 Scapholunate advanced collapse, magnetic resonance imaging of, 732

Scintigraphy. See Nuclear medicine techniques.

Scleroderma, facial manifestations of, 953, 956-966

clinical, 959

in systemic disease, 958, 966 pathophysiology of, 958-959

treatment of, 959-966

in dermatomyositis, 937

linear, facial manifestations of, 953, 956-

physical therapy for, 1013

Scoring methods, for rheumatoid arthritis, 457-470

Bluhm, 466 comparison of, 466-468

criteria for, 457-458 detailed, 463-466

Freedman-Steinberg, 462

Genant, 464, 466 global, 460-463

Gofton-O'Brien, 462, 466

Kaye, 464-466, 468

Kellgren, 460

Larsen, 461-462, 466

Sharp, 463-464, 467-468 Steinbrocker, 459-460, 467

types of, 458-459

Seborrheic dermatitis, in HIV infection, 66 Selenium deficiency, immune response to,

Septic arthritis, arthrography in, 505-515 hip, 511, 513

shoulder, 511

with rheumatoid arthritis, 531

bacteriology of, 505

clinical abnormalities in, 506

computed tomography in, 549

HIV infection with, 149-156

acromioclavicular joint involvement,

149 - 150

diagnosis of, 153-154 in hemophiliacs, 150

in intravenous drug abusers, 150-151 opportunistic infection and, 151-154

osteomyelitis with, 152

pyomyositis with, 152-153 treatment of, 153-155

magnetic resonance imaging in, foot, 631 knee, 663

nuclear medicine techniques in, 560-562 osteomyelitis with, 506

pathophysiology of, 505-506

radiography of, 506

Septic bursitis, HIV infection with, 150-151

Shag carpet synovium, 519

Sharp scoring method, for rheumatoid arthritis, 463-464, 467-468

Sheep, retrovirus infection in, HIV infection and, 5-23

Shigella infection, in arthritis pathogenesis, 33. 311-312

Shoes, for juvenile rheumatoid arthritis rehabilitation, 1008

Shoulder, arthrography of, 795-796 in septic arthritis, 511

computed tomography of, 547-548

juvenile rheumatoid arthritis of, physical therapy for, 1003

magnetic resonance imaging of, 693-703. 796

in instability, 698-701 in rotator cuff tears, 697-698

in shoulder impingement syndrome, 694_698

in subdeltoid bursitis, 696-697

in supraspinatus tendonitis, 697

in synovial pathology, 702

technical considerations in, 693-694

radiography of, 795

ultrasonography of, 490-491, 493, 496,

Shoulder impingement syndrome, magnetic resonance imaging of, 694-698

Sicca syndrome, in Sjögren's syndrome, 99-Siögren's syndrome. HIV infection with, 168

vs. diffuse infiltrative lymphocytosis, 99-Skin disorders. See also Dermatomyositis;

Psoriasis: Psoriatic arthritis: Scleroderma.

in HIV infection, 47

in L-tryptophan-induced eosinophiliamyalgia syndrome, 431-432

Skin test, in food allergy diagnosis, 245-246 Slapped cheek syndrome, arthritis in, 866 SLE. See Systemic lupus erythematosus.

Soft tissue, magnetic resonance imaging of, foot, 633-634

ultrasonography of, 488, 502

Sonography. See Ultrasonography.

Spinal cord infection, magnetic resonance imaging in, 784, 790

Spine, arthritis of, in HIV infection, 29-30, 46-47

cervical. See Cervical spine.

infection of, magnetic resonance imaging in, 773-794

disk space involvement in, 786-787 gadolinium-enhanced (contrast), 785Spine (Continued)

in epidural abscess, 775, 778, 784,

in meningitis, 785, 790 in myelitis, 784, 790

in osteomyelitis, 786-787

in paraspinal abscess, 784, 787, 790 noncontrast (plain), 773-785

pseudarthrosis of, imaging of, 813-815 Splenomegaly, in common variable immunodeficiency, 299

Splinting, in dermatomyositis, 938 in juvenile rheumatoid arthritis, 1002, 1004-1008

Spondyloarthropathy. See also specific disease, e.g., Reiter's syndrome. gastrointestinal antigens in, 315 HIV infection with, 43-58

undifferentiated, HIV infection with, 45-

Sporothrix schenckii infection, in septic

arthritis, 151 Staphylococcal infection, arthritis in, 861-

Staphylococcus aureus, in epidural abscess,

in septic arthritis, 149-151, 153-154

Staphylococcus pneumoniae, in septic arthritis, 150, 154

Steinbrocker scoring method, for rheumatoid arthritis, 459-460, 467

Sternoclavicular joint, computed tomography of, 544-545, 547

Strengthening exercises, for pediatric patients, 1002-1008

Streptococcal infection, arthritis in, 861 Stress fractures, magnetic resonance imaging of, foot, 633-634

hip, 680, 682 knee, 650

Subacromial bursa. See Subdeltoid bursa. Subaxial subluxation, in cervical spine rheumatoid arthritis, 760, 762

Subdeltoid bursa, arthrography of, 534, 537 magnetic resonance imaging of, 696-697 ultrasonography of, 496

Substance P, in pain mechanism, 992 Subtalar joint, computed tomography of, 553-554

Sulfasalazine, in arthritis, with gastrointestinal disorders, 316 in juvenile rheumatoid arthritis, 874, 879-880, 903

in psoriatic arthritis, in HtV-positive patients, 39

Superantigens, in arthritis, 862 Supraspinatus tendonitis, magnetic

resonance imaging of, 697 Sympathetic nerve block, in reflex sympathetic dystrophy pain, 994 Synovial fluid, cytokines in, 18-19

HIV in, 49

in septic arthritis, 154

pathologic changes in, in HIV infection,

viral particles in, 15-16

Synovial spaces, ultrasonography of, 499,

Synovitis, DeQuervain's, magnetic resonance imaging of, 738 in HIV infection, 49, 52-53

in juvenile rheumatoid arthritis, persistence of, radiographic assessment of, 894-897

in spondyloarthropathy, with HIV infection, 46

nuclear medicine techniques in, 586, 589-

of hip, magnetic resonance imaging of,

of knee, magnetic resonance imaging of, 655-659

of wrist, magnetic resonance imaging of, 736, 738

pigmented villonodular, arthrography of, 516, 519

magnetic resonance imaging of, 655-659, 684

transient, in children, magnetic resonance imaging in, 686

Synovium, chondromatosis of, arthrography of. 523 cobblestoned, 519

lining of, magnetic resonance imaging of, 625

millet seed, 523

pathologic changes in, in HIV infection, 34-35

shag carpet, 519

viral particles in, 13-14

Systemic lupus erythematosus, food allergy and, 264

HIV infection with, 177-183

in childhood, outcome of, 921-930 treatment of, 923-928

pathogenesis of, amino acids in, 323-332

treatment of, in pediatric patients, 923-928

T lymphocytes, activation of, by enterotoxins, 862

in juvenile rheumatoid arthritis, 846 function of, dihomogamma linolenic acid effects on, 420-421

proliferation of, in rheumatoid arthritis, 863-864

Talocalcaneal coalition, computed tomography of, 554

Talus, avascular necrosis of, magnetic resonance imaging of, 632

Tarsal coalition, magnetic resonance imaging of, 634

Tarsal ganglion, magnetic resonance imaging of, 634

tat gene, in retroviruses, 7-11, 19

Technetium-99m radiopharmaceuticals, in arthritis imaging, 586, 589-590 in bone disorder imaging, 560

Temporal artery, eosinophilic vasculitis of, in HIV infection, 140

Temporomandibular joint disorders, in juvenile rheumatoid arthritis, 943–953 physical therapy for, 1002

Tender points, in juvenile fibromyalgia, 995–996

Tendon(s), magnetic resonance imaging of, foot, 633-634 wrist, 736, 738

ultrasonography of, 487-498

Tendonitis, supraspinatus, magnetic resonance imaging of, 697 ultrasonography of, 490, 493

Thiamine deficiency, immune responses to,

Thrombocytopenia, in HIV infection, 164 Thrombosis, deep venous, in rheumatoid arthritis, 805–806

Thromboxanes, synthesis of, 373–378, 380 Thymus, hyperplasia of, in diffuse

infiltrative lymphocytosis, 105
Toes, juvenile rheumatoid arthritis of,

physical therapy for, 1008
Tolerance, to food. See also Food,
intolerance to.

mechanisms for, 292
Tolmetin, in psoriatic arthritis, with HIV
infection, 68

in Reiter's syndrome, with HIV infection, 68

Tomography, conventional, in ankylosing spondylitis, 814

Toxic shock syndrome, arthritis in, 861-862 Toxins, in arthritis etiology, 861-862

in Kawasaki disease pathogenesis, 909 Toxoplasmosis, hypertrophic arteritis in, 141

Traction, in hip arthritis, 1006 Transcutaneous nerve stimulation, in reflex sympathetic dystrophy pain, 994

Transforming growth factor-beta, in juvenile rheumatoid arthritis, 849

Transient marrow edema syndrome, of hip, magnetic resonance imaging of, 675, 677, 680

Triamcinolone, in scleroderma, 959
Triangular fibrocartilage complex, magnetic resonance imaging of, 730

Tricyclic antidepressants, in juvenile rheumatoid arthritis, 992

Trigger points, in juvenile fibromyalgia, 995–996

Trimolecular complex, in juvenile rheumatoid arthritis, 826-827

Trochanteric bursitis, in HIV infection, 83 Tryptase, in mast cells, 337

L-Tryptophan, in eosinophilia-myalgia syndrome. See under Eosinophiliamyalgia syndrome.

Tube feedings, nocturnal, in juvenile rheumatoid arthritis, 410–411 Tuberculosis, rheumatoid arthritis in, 862–

864
Tuberculous arthritis, arthrography of 523-

Tuberculous arthritis, arthrography of, 523–524, 528

Tumor(s), magnetic resonance imaging of, elbow, 711, 713, 719 wrist, 727

Tumor necrosis factor, in juvenile rheumatoid arthritis, 849-850

in Kawasaki disease, 910 interactions with eicosanoids, 235-236

Tyrosine deficiency, autoimmune disease and, 224

Ulcerative colitis, arthritis with, 312-313

Ultrasonography, of biceps tendon, 496 of bone, 487

of cartilage, 487

of cysts, 487-488, 496, 502 of foot, in tendon disorders, 496

of hand, in tendon disorders, 496 of hematoma, 499

of hematoma, 499 of knee, in cystic disorders, 502

of musculoskeletal system, 487-504

of myositis, 499

of popliteal cyst, 803 of rotator cuff, 491, 493, 796

of shoulder, 490-491, 493, 496, 796

of soft tissue, 488, 502 in foreign body detection, 502

of subdeltoid bursa, 496 of synovial spaces, 499, 502

of tendons, 487–498

of wrist, in ganglion cyst, 496

venous, in deep vein thrombosis, 805–806
vs. magnetic resonance imaging, 617

Ultrasound, in physical therapy, 1009–1010 Ultraviolet light, in psoriasis/psoriatic arthritis, with HIV infection, 39, 66–67

Unproved remedies, for arthritis, 197–202, 273–285, 346–347, 406–407

Urethritis, in Reiter's syndrome, 33, 61

Varicella infection, central nervous system angiitis in, 140

Vascular lesions, in L-tryptophan-induced eosinophilia-myalgia syndrome, 432 Vasculitis, food allergy and, 266

HIV infection with, 131-147, 169, 186-

angiocentric immunoproliferative lesions, 135-138, 142

central nervous system anglitis, 138– 142

classification of, 131-132

clinical considerations in, 143-144 eosinophilic, 140

hypersensitivity disorders, 134–135 leukocytoclastic, 134–135

lymphomatoid granulomatosis, 135–138 opportunistic infections in, 141 pathophysiology of, 141–143

polyarteritis nodosa-like syndromes, 132–133

in dermatomyositis, 933-935 in Kawasaki disease, 911-912

Venography, in popliteal cyst evaluation, 803

vif gene, in retroviruses, 7-9

Viral infections. See Retrovirus infections; specific type, e.g., Human immunodeficiency virus infection.

Visna-Maede virus infection, in sheep, HIV infection and, 5-23

Visual analogue scale, in Pediatric Pain Questionnaire, 988–990

Vitamin(s), deficiencies of, autoimmune disease and, 228-229 immune responses to, 204-208

Vitamin C (ascorbic acid), in rheumatoid arthritis, 266

cpr gene, in retroviruses, 7-9 cpu gene, in retroviruses, 7, 9

Weight loss, in fasting, 351–352 in rheumatoid arthritis, dietary therapy and, 278, 282–283 Whipple's disease, arthritis in, 314 Wrist, arthrography of, 531 in instability, 532-533

juvenile rheumatoid arthritis of, physical therapy for, 1004

magnetic resonance imaging of, 721-739 anatomic considerations in, 722

in arthritis, 738

in carpal tunnel syndrome, 722, 727 in instability, 732, 736

in osteonecrosis, 727

in tendon abnormalities, 736, 738

in tumors, 727

in ulnar-sided pain, 730 technique for, 721

technique for, 721

triangular fibrocartilage complex, 730 ultrasonography of, in ganglion cyst, 496

Xerostomia, in diffuse infiltrative lymphocytosis syndrome, 103 in Sjögren's syndrome, 99–102

Yersinia infection, in arthritis pathogenesis, 33, 65, 312-313, 366

Zidovudine (azidothymidine, AZT), in HIV infection, 123, 127

with arthritis, 55

with diffuse infiltrative lymphocytosis, 111-112

with psoriasis, 67

with psoriatic arthritis, 39, 68

with Reiter's syndrome, 68

with systemic lupus erythematosus, 178–182

in psoriasis, 72 Zimbabwe, HIV infection in, arthritis with,

89–97

Zinc, deficiency of, autoimmune disease
and, 229–231

immune responses to, 209-210 in rheumatoid arthritis, 266-267

